Colorectal cancer (CRC) is a globally prevalent malignancy with high morbidity and mortality rates, closely linked to aberrant epigenetic modifications. Among these, pseudouridine (Ψ), one of the most abundant RNA chemical modifications, plays a pivotal role in tumorigenesis by regulating mRNA stability, translation efficiency, and splicing processes. Recent studies have demonstrated that the small-molecule inhibitor Pyrazofurin, targeting the pseudouridine synthase DKC1, exhibits significant anti-tumor activity, suggesting Ψ modification as a promising therapeutic strategy for CRC. However, the dynamic changes and clinical implications of transcriptome-wide Ψ modifications in CRC remain poorly understood.

Among adults ages 18-49 (median age of 41 years) who were born with a hole in the upper chambers of their heart known as patent foramen ovale (PFO), strokes of unknown cause were more strongly associated with nontraditional risk factors, such as migraines, liver disease or cancer, rather than more typical factors such as high blood pressure.

*Note – this is an early press release from the European Congress on Obesity in Malaga, Spain, 11-14 May. Please credit the congress when using this research.*

New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) and published in The Journal of Internal Medicine shows that, in survivors of breast cancer, having an unhealthy metabolic profile or so called ‘metabolic syndrome’ increases the risk of breast cancer recurrence by 69%, and subsequent breast cancer mortality by 83%. The study is by Dr Sixten Harborg, Department of Oncology, Aarhus University/Aarhus University Hospital, Aarhus, Denmark. and Department of Nutrition, Harvard T.H. Chan School of Public Health, MA, USA, and colleagues.